History

Footsteps of KOLON Life Science, pursuing beyond healthy life

  • 2008~PresentPeriod of Takeoff
    • 2015Acquisition of approval for Clinical Phase III of ‘TissueGene-C’ (USFDA)
    • 2013Acquisition of approval for Clinical Phase III of 'TissueGene-C' (KFDA)
    • 2012Completion of new active pharmaceutical ingredients cGMP plant (Chungju)
    • 2012Change of CEO(CEO, Woo-Suk Lee)
    • 2012Change of headquarter location ((Byulyang-dong) 13, KOLONro, Gwachun-si, Kyunggi-do)
    • 2011Completion of new antimicrobial and water treatment agent plant (Kimchun)
    • 2009Listed on KOSDAQ
    • 2015
      05

      Acquisition of approval for Clinical Phase III of ‘TissueGene-C’ (USFDA)

    • 2014
      06

      Completion of new Biopharmaceutical plant (Chungju)

      04

      Conclusion of MOU with University of California, Sandiego for R&D cooperation

    • 2013
      08

      Acquisition of approval for Clinical Phase III of 'TissueGene-C' (KFDA)

    • 2012
      10

      Completion of new active pharmaceutical ingredients cGMP plant (Chungju)

      03

      Change of CEO(CEO, Woo-Suk Lee)

      02

      Change of headquarter location ((Byulyang-dong) 13, KOLONro, Gwachun-si, Kyunggi-do)

    • 2011
      04

      Approval of Clinical Phase II of TissueGene-C(S) by KFDA

      04

      Completion of new antimicrobial and water treatment agent plant (Kimchun)

    • 2010
      12

      Acquisition of approval for Clinical Phase IIb of 'TissueGene-C'

      11

      Procurement of site for new plant in Chungju Company City

      07

      Change of largest shareholder to KOLON Corporation (Included into holding company as a subsidiary company)

      07

      Decision made to construct new antimicrobial and water treatment agent plant

    • 2009
      12

      Selection of ‘cervical cancer treatment vaccine’ project, a business of Ministry of Health and Welfare, health and medical treatment R&D business

      12

      Conclusion of contract to adopt KR Biotech’s ‘cervical cancer treatment vaccine’ technology

      05

      Completion of active pharmaceutical ingredients cGMP plant within Eumseong factory

      04
      • Triumph(TriumphⅡ Investments (Ireland),
      • spendthrift(UOB JAIC Venture Bio Investments LTD)
      • convertible redeemable preferred stock changed to common stock and additional listing
      04

      Approval of screening of going public on the KOSDAQ, Korea Exchange

      02

      Acquisition of approval for Clinical Phase IIa of 'TissueGene-C'; Korea KFDA

    • 2008
      10

      Approval of screening in preparation of going public on the KOSDAQ, Korea Exchange

      06

      Claim for a screening in preparation of going public on the KOSDAQ, Korea Exchange

      01

      Conclusion of contract to adopt ProCell’s new drug technology for treatment of Parkinson’s disease

  • 2006~2007Period of Foundation
    Establishment
    • 2007Commercialization of TissueGene-C chosen as Ministry of Commerce, Industry and Energy’s biostar business
    • 2006Conclusion of contract to adopt new bio medicine (p40-hFc, treatment for Parkinson’s disease)
    • 2006Approval of Clinical Phase I of TissueGene-C by FDA and KFDA
    • 2006Take over of active pharmaceutical ingredients and eco-friendly materials business from KOLON Industries, Inc. and KOLON Chemical, Co.
    • 2006Change of name to KOLON Life Science, Inc.
    • 2007
      12

      Conclusion of contract to adopt global new medicine candidate material technology for anti-influenza

      03

      Acquisition of ISO 9001 certification for Kimchun plant

      02

      Commencement of Clinical Phase I of 'TissueGene-C' in Korea and U.S.

      01

      Conclusion of contract to adopt Genexine’s new bio medicine, p40-hFc(autoimmune disease drug)

      01

      Issuing of convertible redeemable preferred stock for spendthrift(UOB JAIC Venture Bio Investments LTD)

      01

      Acquisition of IRB approval for 'TissueGene-C' from Korea Clinical Research Organization

    • 2006
      12

      Acquisition of approval for Clinical Phase I of 'TissueGene-C'; Korea KFDA, acquisition of IRB approval for ‘TissueGene-C’ from U.S. Clinical Research Organization

      11

      Issuing of convertible redeemable preferred stock for triumph (Triumph II Investments (Ireland) Limited)

      07

      Acquisition of approval for Clinical Phase I of 'TissueGene-C'; U.S. FDA

      04

      Success in commercialization of newly developed-Argatroban(anticoagulant)

      03

      Acquisition of ISO 9001/ISO 14001, OHSAS 18001 for Incheon plant’s lab

      01
      • Take over of active pharmaceutical ingredients and eco-friendly material business from KOLON Chemical Co.
      • change of name to KOLON Life Science, Inc.
  • 2000~2005Period of Establishment
    • 2005Selection of TissueGene-C commercialization as Ministry of Commerce, Industry, and Energy’s biostar project
    • 2002Conclusion of contract for distribution of Unilever’s antimicrobial
    • 2002Selection of TissueGene-C as Ministry of Health and Welfare’s health and medical treatment technology promotion project
    • 2001U.S. patent in relation to cell mediated gene therapy
    • 2000Establishment of TissueGene Asia,Ltd
    • 2005
      12

      Take over of active pharmaceutical ingredients and eco-friendly materials business from KOLON, Inc.

      09

      Filing of application for KFDA IND of 'TissueGene-C'

      08

      Selection of ‘Degenerative arthritis treatment TissueGene-C commercialization’ as Ministry of Commerce, Industry, and Energy’s biostar project

      06

      Filing of application for U.S. FDA IND of 'TissueGene-C'

      04

      Success in commercialization of new development
      -Voglibose (diabetes medicine)

      02

      Acquisition of patent for, 'The method of manufacturing hyaluronic acid using hyaluronic’(472007)

    • 2004
      09

      Acquisition of pharmaceutical-related patent (The method of manufacturing 2-(4-Halomethylphenyl) propionic acid-448641)
      (The new method of manufacturing phenylpropionic acid derivative-448642)

      09

      Acquisition of U.S. patent for ‘TissueGene-C’ related "gene therapy using TGF-b1"' (USP 6,797,703)

      05

      Acquisition of anticancer agent related patent (The manufacturing method of, and pharmacological compounds containing, sulfonamide derivative for neovascularization inhibition-0432928)

      04

      Success in commercialization of new development
      - KP-324 (eco-friendly flame retardant), 5-FC (intermediate ingredient of AIDS medicine)

    • 2003
      11

      Acquisition of anticancer agent related patent (The manufacturing method of, and pharmacological compound containing paclitaxel or its derivative-406739)

      04

      Success in commercialization of medicine and pharmaceutical ingredient
      -Nadifloxacin (antibiotic) and Zaltoprofen (anti-inflammatory drug)

    • 2002
      11

      Conclusion of contract for distribution of KP-1465(antioxidant) to 'Shiba Special Chemical'

      07

      Selection of 'TissueGene-C' as Ministry of Commerce, Industry, and Energy’s health & medical technology promotion project (Commercialization of Tissuegene-C or development of its analogue for the treatment of generative arthritis using cell-mediated gene therapy)

      06

      Conclusion of contract for distribution of cephalosporin intermediates to ‘GSK’

      04

      Conclusion of contract for distribution of CleanBio to ‘Unilever’

      04

      Success in commercialization of medicine and pharmaceutical ingredient – Felbinac(anti-inflammatory), Levofloxacin(antibiotic)

      03

      Filing of patent application for manufacturing method of stomach ulcer medicine, Lansoprazole (Teuk2002-11867Ho)

    • 2001
      12

      Acquisition of BGMP certificate for Incheon plant

      10

      Acquisition of cell mediated gene therapy related U.S. patent (Regeneration of cartilage in mammal using fibroblasts transformed to contain TGF-B1 (TissueGene-C analogue) producing factor -USP 6,315,992)

      07

      Filing of anticancer related patent (A method of manufacturing N-Alkynyloxycarbonyl-5-fluorocytosine derivatives or antibiotics containing them as an active ingredient)

      04

      Acquisitino of anticancer related patent (Oral anticancer compound containing hydrosoluble paclitaxel prodrug compound and flabonoid compound) - Korea: 2001-91856, USA: 10/221774, Japan: 2001-576083, EU: 01926177.5

    • 2000
      04

      Establishment of Korea TissueGene Asia, Ltd.